1. Why Is Drug Distribution into Tumors Important?
A drug cannot produce a pharmacologic effect in a tumor simply because it is present in plasma. The drug must reach the relevant tumor compartment, remain available long enough, and—depending on its mechanism—reach the appropriate cellular or molecular target.
This creates a fundamental distinction between systemic exposure and tumor exposure. Plasma concentration is often relatively easy to measure, whereas drug concentration within tumors can be substantially more difficult to characterize.
Tumor exposure is the result of multiple processes between systemic circulation and the relevant site of pharmacologic action.
2. What Makes Tumor Distribution Different?
Solid tumors are structurally and physiologically heterogeneous. Their vasculature, extracellular matrix, interstitial fluid pressure, cellular density, pH, and blood flow can differ substantially both between tumors and within the same tumor.
These characteristics can create several sequential barriers between plasma and a drug target.
| Step | Process | Potential determinant |
|---|---|---|
| 1. Delivery to tumor | Drug is transported through the systemic circulation to tumor blood vessels. | Blood flow, cardiac output, tumor perfusion, vascular architecture |
| 2. Vascular transfer | Drug moves from blood across the tumor microvascular barrier. | Permeability, endothelial structure, molecular size, lipophilicity |
| 3. Interstitial transport | Drug moves through the extracellular tumor space. | Diffusion, convection, extracellular matrix, interstitial pressure |
| 4. Cellular uptake | Drug enters tumor cells when intracellular action is required. | Membrane permeability, transporters, endocytosis |
| 5. Target interaction | Free drug interacts with its molecular target. | Binding affinity, target abundance, competition |
The importance of each step depends strongly on the drug. A small, lipophilic molecule and a large antibody can encounter very different distribution barriers.
3. Tumor Perfusion and Drug Delivery
The first requirement for systemic delivery is that drug-containing blood reaches the tumor. Tumor perfusion therefore provides an important link between systemic exposure and local delivery.
Regions of a tumor may be well perfused while other regions receive relatively little blood flow. Necrosis, abnormal vascular architecture, compression of blood vessels, and elevated interstitial pressure can contribute to spatially heterogeneous delivery.
where \(Q_T\) represents tumor blood flow and \(C_{\mathrm{blood}}\) is the drug concentration in blood entering the tumor.
This simplified relationship does not mean that blood flow alone determines tumor concentration. Once drug reaches the tumor vasculature, transfer across the vascular barrier and subsequent transport through the tissue still matter.
4. Crossing the Tumor Vasculature
After drug reaches tumor blood vessels, it must cross the vascular barrier before entering the tumor interstitial space.
For many small molecules, transvascular movement can involve diffusion through endothelial barriers. For larger molecules, including monoclonal antibodies, transport may be substantially slower and can involve mechanisms such as convection, extravasation, and receptor-mediated processes.
A conceptual relationship for vascular transfer is:
Here \(PS\) represents a permeability-surface-area term. The expression is intentionally simplified: real tumor models may distinguish blood from plasma, include blood flow explicitly, account for unbound fractions, or use nonlinear transport.
Small molecules versus large molecules
| Characteristic | Small molecules | Large biologics |
|---|---|---|
| Typical molecular size | Small | Large |
| Vascular permeability | Often relatively high, depending on properties | Often much lower |
| Interstitium penetration | Can be relatively rapid | Can be slower and spatially limited |
| Cell entry | May occur by passive diffusion or transporters | Often requires specialized uptake mechanisms if intracellular action is needed |
| Binding effects | Protein and tissue binding can be important | Target-mediated binding can strongly influence distribution |
These are general tendencies rather than universal rules. Molecular properties, tumor biology, dosing, target expression, and formulation can substantially alter the observed behavior.
5. Transport Through the Tumor Interstitium
Once drug leaves the vasculature, it must move through the extracellular space to reach cells or extracellular targets.
For a small molecule undergoing diffusion, a simplified description is based on Fick's law:
where \(J\) is flux, \(D_{\mathrm{eff}}\) is an effective diffusion coefficient, and \(C\) is concentration.
In tumors, the effective transport process can be affected by extracellular matrix composition, tortuosity, binding to tissue components, cellular density, and fluid movement.
Convection may also contribute. However, elevated interstitial fluid pressure can reduce the pressure gradient that would otherwise drive fluid movement from tumor vessels into surrounding tissue.
6. The EPR Effect: Useful Concept, Not a Universal Explanation
The enhanced permeability and retention (EPR) effect describes increased macromolecular accumulation that can occur in some tumors as a consequence of abnormal vasculature and impaired drainage.
The concept has been influential in the development of nanomedicines and other macromolecular delivery strategies. However, the magnitude and consistency of EPR-mediated accumulation can vary substantially across tumor types, animal models, individual tumors, and patients.
It is therefore useful to distinguish two ideas:
- Accumulation: the amount of drug or carrier present in tumor tissue.
- Effective delivery: the fraction that reaches the relevant biological target in an active form.
A drug can accumulate in tumor tissue without producing a corresponding increase in free intracellular concentration or target engagement.
7. Binding Can Change Tumor Distribution
Drug molecules can bind plasma proteins, extracellular matrix components, cell-surface targets, intracellular proteins, or other tissue components.
Only a fraction of drug may be freely available for movement between compartments. A simple binding relationship can be written as:
where \(B_{\max}\) represents the available binding capacity and \(K_D\) is the equilibrium dissociation constant.
When binding is approximately linear over the concentration range of interest, it can sometimes be represented with a distribution coefficient. At higher concentrations, binding can become saturable and therefore nonlinear.
Why binding matters
- Binding can reduce the immediately available free concentration.
- Binding can create a local reservoir of drug.
- High-affinity binding can slow penetration beyond the first cellular layers.
- Target binding can cause nonlinear distribution.
- Binding can produce differences between total and free tumor concentrations.
These mechanisms become especially important for targeted therapeutics and for drugs exhibiting target-mediated drug disposition (TMDD).
8. Target Binding Can Create a Distribution Sink
Suppose a drug binds a tumor target with high affinity. Drug molecules entering the tumor may bind rapidly near the vasculature before they have penetrated deeply into the tissue.
This can produce a phenomenon sometimes described as a binding-site barrier: strong binding can increase local retention while simultaneously limiting the depth of penetration of additional free drug.
Conceptual illustration: strong binding near tumor vessels can create steep spatial concentration gradients. The exact behavior depends on transport and binding kinetics.
This does not mean that strong target binding is always detrimental. Binding can be essential for pharmacologic activity and can increase retention. The important point is that binding changes the relationship between transport and local concentration.
9. Tumor Tissue Concentration Is Not the Same as Intracellular Concentration
For many anticancer therapies, the relevant pharmacologic target is intracellular. In such cases, tumor homogenate concentration may be an incomplete measure of pharmacologically active exposure.
The sequence may be:
Each step can introduce a new barrier or kinetic process.
| Concentration | What it represents | Potential limitation |
|---|---|---|
| Plasma | Systemic circulating exposure | Does not directly establish tumor exposure |
| Total tumor | Drug measured in tumor tissue | Includes multiple tissue compartments and bound drug |
| Interstitial | Extracellular tumor exposure | May not represent intracellular target exposure |
| Intracellular | Drug inside tumor cells | May still include nonspecific or inactive drug |
| Target-site | Drug available at the pharmacologic target | Often difficult to measure directly |
This hierarchy is one reason exposure-response relationships can sometimes be difficult to interpret using plasma concentrations alone.
10. Uptake, Efflux, and Intracellular Drug Levels
Transport proteins can influence both entry into and removal of drug from tumor cells. In some tumors, uptake transporters increase intracellular concentrations, whereas efflux transporters can decrease intracellular exposure.
A conceptual intracellular balance is:
where the individual terms represent inward transport, outward transport, intracellular metabolism, and binding or sequestration processes.
These processes can be concentration-dependent and may be saturable. Consequently, intracellular exposure does not always increase proportionally with plasma exposure.
11. Tumors Are Not Well-Mixed Compartments
A standard compartmental PK model often assumes that drug concentration within a compartment can be represented by a single value. A solid tumor may violate this assumption strongly.
Within one tumor, regions can differ in:
- Blood flow and vascular density.
- Vascular permeability.
- Interstitial fluid pressure.
- Extracellular matrix density.
- Cell density.
- Oxygenation and pH.
- Target expression.
- Drug metabolism and transporter expression.
- Distance from functioning blood vessels.
Therefore, two cells within the same tumor can experience different drug concentrations even when the measured average tumor concentration is identical.
12. Tumor-to-Plasma Ratios
A simple way to summarize tissue distribution is the tumor-to-plasma concentration ratio:
If the ratio is calculated at a specific time, it describes the relative concentrations at that time. A related steady-state or equilibrium-oriented quantity may be written as:
However, the interpretation of \(K_p\) depends on how and when the concentrations were measured.
Total versus unbound distribution
For pharmacologic interpretation, the unbound fraction can be particularly important. A conceptual unbound tissue-to-plasma ratio is:
where \(C_u\) denotes unbound concentration.
Total concentration ratios can be strongly influenced by binding. Consequently, a large total tumor-to-plasma ratio does not necessarily imply a large unbound tumor exposure.
13. How Can Tumor Distribution Be Represented in PK Models?
The appropriate model depends on the scientific question and the available data. A simple tumor compartment can be useful when the primary objective is to describe the average tumor concentration-time profile.
A basic tumor compartment can be written as:
where \(A_P\) represents drug amount in the plasma or central compartment and \(A_T\) represents drug amount in the tumor compartment.
The model can be expanded to represent additional mechanisms.
| Model structure | Potential purpose |
|---|---|
| Plasma + tumor compartment | Describe average tumor distribution kinetics |
| Plasma + interstitial + cellular compartments | Separate extracellular and intracellular exposure |
| Permeability-limited model | Represent vascular transfer explicitly |
| PBPK tumor model | Connect tumor physiology, blood flow, permeability, binding, and drug properties |
| Spatial reaction-diffusion model | Describe concentration gradients through tumor tissue |
| Target-mediated model | Represent saturable binding and target turnover |
| PK/PD tumor model | Link tumor exposure to biomarker or efficacy endpoints |
14. Perfusion-Limited Versus Permeability-Limited Distribution
One of the useful conceptual distinctions in tissue PK is whether distribution is controlled primarily by blood flow or by the ability of drug to cross the vascular barrier.
Perfusion-limited distribution
If vascular transfer is sufficiently rapid relative to blood delivery, tumor uptake may be strongly influenced by blood flow. In a simplified view, the tissue rapidly approaches the concentration delivered by the incoming blood.
Permeability-limited distribution
If vascular transfer is slow, permeability becomes an important determinant of tumor exposure. Increasing blood concentration may then have a delayed or attenuated effect on tissue concentration.
| Feature | Perfusion-limited | Permeability-limited |
|---|---|---|
| Dominant constraint | Blood delivery | Vascular transfer |
| Tumor equilibration | Relatively rapid | Relatively slow |
| Importance of blood flow | High | Still relevant but not necessarily dominant |
| Importance of permeability | Lower | High |
| Potential relevance | Highly perfused tissues or rapidly exchanging compounds | Large molecules or poorly permeable barriers |
Real tumors can exhibit mixed behavior, and the dominant limitation can change with drug properties, dose, time, and tumor region.
15. Tumor Distribution in PBPK Models
Physiologically based pharmacokinetic (PBPK) models attempt to connect drug disposition to physiological and biochemical characteristics of the organism.
A tumor compartment can incorporate quantities such as:
- Tumor blood flow.
- Tumor volume.
- Vascular permeability.
- Surface area available for exchange.
- Interstitial volume.
- Intracellular volume.
- Plasma and tissue binding.
- Transporter activity.
- Target expression and turnover.
- Drug-specific physicochemical properties.
A simplified permeability-limited tumor model might distinguish vascular, interstitial, and cellular spaces:
Here \(V\) denotes the vascular space and \(I\) the interstitial space. A cellular uptake term \(R_{\mathrm{cell}}\) can then connect extracellular exposure to intracellular drug.
The purpose of such a model is not to reproduce every microscopic feature of a tumor. Rather, it provides a structured framework for testing how measurable physiological and drug-specific factors could influence tumor exposure.
16. Distribution of Monoclonal Antibodies into Tumors
Monoclonal antibodies present distinctive tumor distribution challenges because of their large molecular size and complex interactions with the tumor microenvironment.
After entering tumor tissue, an antibody may bind a target or nonspecifically interact with tissue components. High-affinity target binding can increase retention but may also reduce the depth of penetration from blood vessels.
Antibody distribution can therefore depend on a combination of:
- Systemic antibody concentration.
- Tumor blood flow.
- Vascular permeability.
- Convective and diffusive transport.
- Antibody binding affinity.
- Target abundance.
- Target internalization.
- Antibody catabolism.
- Tumor size and architecture.
17. Tumor Distribution Is Dynamic
Tumor distribution should generally be viewed as a time-dependent process rather than a fixed tissue partition coefficient.
After dosing, plasma concentration may rise rapidly while tumor concentration increases more slowly. During the elimination phase, tumor concentration may remain elevated after plasma concentration has begun to decline.
Conceptual example: tumor concentration may rise and fall more slowly than plasma concentration because distribution introduces additional kinetic delays.
This temporal delay can be represented using a tumor compartment, an effect compartment, or a more mechanistic distribution model depending on the available data.
18. Worked Example: Estimating Tumor-to-Plasma Exposure
Consider a hypothetical small-molecule anticancer drug. At a particular sampling time, the measured plasma concentration is 10 mg/L and the measured total tumor concentration is 4 mg/L.
Step 1: Calculate the tumor-to-plasma ratio
The measured total tumor concentration is therefore 40% of the measured plasma concentration at that time.
Step 2: Interpret the ratio carefully
A \(K_p\) of 0.40 does not by itself mean that only 40% of the administered dose reached the tumor. \(K_p\) is a concentration ratio, not a dose fraction.
It also does not establish that the pharmacologically active concentration is 4 mg/L. The tumor measurement may contain drug in multiple compartments and may include both bound and unbound drug.
Step 3: Consider unbound exposure
Suppose additional measurements indicate:
- Unbound plasma concentration = 2 mg/L.
- Unbound tumor concentration = 1 mg/L.
The unbound tumor-to-plasma ratio is 0.50, which differs from the total concentration ratio of 0.40.
19. How Is Tumor Drug Distribution Measured?
Tumor drug concentrations can be measured using several approaches, each answering somewhat different questions.
| Approach | What it can provide | Important consideration |
|---|---|---|
| Tumor homogenate | Average total concentration in sampled tissue | Spatial information is lost |
| Microdialysis | Potentially measures extracellular unbound exposure | Sampling recovery and local perturbation must be considered |
| Imaging | Spatial distribution of labeled drug or tracer | Signal may not equal pharmacologically active concentration |
| Autoradiography | Spatial tissue distribution | Typically requires labeled compound and specialized analysis |
| Laser capture / spatial methods | Regional or cellular information | Technically demanding and potentially limited in quantitative interpretation |
| Biomarkers | Evidence of target engagement or downstream effect | Indirect measure of drug concentration |
The ideal measurement depends on the scientific question. If the question concerns total tumor accumulation, homogenate measurements may be informative. If the question concerns extracellular target exposure, a measurement closer to unbound interstitial concentration may be more relevant.
20. Tumor PK Versus Conventional Plasma PK
Conventional plasma PK focuses on concentration in the systemic circulation. Tumor PK extends the analysis to the time course of drug exposure within tumor tissue.
| Feature | Plasma PK | Tumor PK |
|---|---|---|
| Primary measurement | Plasma or blood concentration | Tumor tissue, interstitial, cellular, or target-site concentration |
| Sampling | Often relatively straightforward | More invasive or technically complex |
| Spatial information | Minimal | Potentially important |
| Major determinants | Absorption, distribution, metabolism, elimination | Perfusion, permeability, transport, binding, cellular uptake, local metabolism |
| Model complexity | Often compartmental or population PK | May require tissue, PBPK, spatial, or mechanistic models |
The two should not be viewed as competing descriptions. Plasma PK provides an important systemic input into tumor PK, while tumor PK provides information about the exposure at or near the site of disease.
21. Linking Tumor Exposure to Pharmacodynamics
The ultimate purpose of characterizing tumor distribution is often to understand whether sufficient active drug reaches the target to produce a biological effect.
For a concentration-driven effect, a simple \(E_{\max}\) model can be written as:
For tumor pharmacology, however, the most relevant concentration may not be plasma concentration. Depending on the mechanism, the appropriate driver may be free tumor concentration, intracellular concentration, target occupancy, pathway inhibition, or another proximal biomarker.
This distinction is central to PK/PD modeling and pharmacometrics: the model should connect the exposure metric to the biological process that actually drives the endpoint.
22. How Poor Tumor Distribution Can Contribute to Resistance
Pharmacologic resistance can arise through many mechanisms, and inadequate drug distribution is only one possible contributor. Nevertheless, heterogeneous exposure can create regions of a tumor in which drug concentrations remain below those required for sustained target inhibition.
Potential contributors include:
- Poor vascular perfusion.
- Limited vascular permeability.
- Long diffusion distances.
- Dense extracellular matrix.
- High target-mediated binding near blood vessels.
- Drug efflux.
- Intracellular sequestration.
- Local metabolism.
- Low target expression in some tumor regions.
A useful conceptual comparison is:
where \(C_{\mathrm{effective}}\) represents a concentration range associated with the desired biological effect and \(x\) represents position within the tumor.
If \(C_{\mathrm{active}}(x,t)\) varies substantially across the tumor, some regions may experience adequate exposure while others do not.
23. A Practical Workflow for Modeling Tumor Distribution
- Define the biological question. Are you interested in total accumulation, free interstitial exposure, intracellular exposure, target engagement, or efficacy?
- Characterize plasma PK first. Tumor distribution models generally depend on the systemic concentration-time profile as an input.
- Identify the relevant tumor compartments. Decide whether a single tumor compartment is sufficient or whether vascular, interstitial, and cellular spaces need to be distinguished.
- Consider the dominant transport mechanism. Determine whether perfusion, permeability, diffusion, convection, active transport, or binding is likely to control the observed behavior.
- Specify binding processes. Include linear or nonlinear binding where supported by the data and biology.
- Incorporate tumor heterogeneity when necessary. A spatial model may be warranted if average tumor concentration cannot answer the scientific question.
- Link exposure to pharmacodynamics. Identify the concentration or biomarker that is mechanistically closest to the drug's effect.
- Evaluate model adequacy. Examine observed-versus-predicted concentrations, residuals, parameter plausibility, and predictive performance.
- Use the model for simulation. Explore how changes in dose, clearance, permeability, binding, tumor physiology, or target expression affect tumor exposure.
24. What Tumor Concentration Does Not Tell Us Automatically
Tumor concentration data are valuable, but several interpretation issues should be considered.
- Total tumor concentration is not necessarily free concentration.
- Tumor concentration is not necessarily intracellular concentration.
- Intracellular concentration is not necessarily target-site concentration.
- A tumor-to-plasma ratio is not a fraction of dose delivered to the tumor.
- A high tissue concentration does not automatically imply pharmacologic activity.
- A low average tumor concentration does not necessarily mean every region is underexposed.
- Homogenized tissue measurements can obscure spatial gradients.
- Animal tumor models may not reproduce human tumor physiology.
- Model parameters may be difficult to identify when tumor sampling is sparse.
- Plasma PK alone may not uniquely determine tumor PK.
25. A Minimal Plasma–Tumor Model
Consider a one-compartment plasma model connected to a tumor compartment.
The plasma amount can be represented as:
The tumor amount is:
Concentrations are obtained from:
Here \(k_{PT}\) describes transfer from plasma to tumor, \(k_{TP}\) describes return from tumor to plasma, and \(k_{T,\mathrm{loss}}\) represents irreversible loss from the tumor compartment.
This model is deliberately simple. It does not explicitly represent tumor blood flow, vascular permeability, interstitial transport, cellular uptake, or target binding.
Its value is that it provides a starting point for asking whether tumor concentration displays a delayed or prolonged time course relative to plasma.
26. What Can Tumor Distribution Models Predict?
Once adequately developed and evaluated, tumor distribution models can be used to explore questions that may be difficult to answer experimentally.
- Expected tumor concentration after a particular dose.
- Time required for tumor exposure to approach systemic exposure.
- Differences between plasma and tumor half-lives.
- Effects of altered clearance on tumor exposure.
- Effects of permeability changes on tumor penetration.
- Potential consequences of target abundance and binding affinity.
- Differences in exposure between hypothetical tumor phenotypes.
- Accumulation during repeated dosing.
- Relationships between tumor exposure and target inhibition.
- Potential exposure gradients within spatial tumor models.
Simulation is particularly useful when several mechanisms could produce similar observed tumor concentrations. Mechanistic models can be used to explore which assumptions are consistent with the available evidence.
27. From Plasma PK to Tumor Pharmacology
A quantitative tumor PK/PD framework connects systemic exposure to the concentration and biological effect at the relevant site.
The important conceptual transition is from asking “What concentration is in plasma?” to asking “What concentration reaches the relevant target in the tumor, when does it get there, and how does it drive the biological response?”
28. Key Takeaways
- Tumor drug exposure is not determined by plasma concentration alone.
- Drug delivery to tumors involves perfusion, vascular transfer, interstitial transport, cellular uptake, binding, and local elimination.
- Tumors are spatially heterogeneous, so average tumor concentration can conceal substantial regional differences.
- Small molecules and large biologics can experience very different vascular and tissue transport limitations.
- The EPR effect can contribute to macromolecular tumor accumulation, but its magnitude is variable and accumulation does not necessarily equal pharmacologically active exposure.
- Binding can increase retention while also altering penetration and creating concentration gradients.
- Total tumor concentration should be distinguished from free, interstitial, intracellular, and target-site concentrations.
- The tumor-to-plasma ratio \(K_p\) summarizes relative concentrations but is not a fraction of the administered dose reaching the tumor.
- The unbound tumor-to-plasma ratio \(K_{p,uu}\) can provide a different perspective when unbound concentrations are relevant to pharmacologic activity.
- Tumor distribution can be represented with simple tumor compartments, permeability-limited models, PBPK models, or spatial reaction-diffusion models depending on the scientific question.
- Monoclonal antibodies can exhibit slow tumor penetration and complex interactions between target binding and tissue distribution.
- Tumor PK is dynamic: tissue concentrations can lag behind plasma concentrations and can persist after plasma concentrations decline.
- For exposure-response modeling, the most useful exposure metric is often the one closest to the biological mechanism of action rather than plasma concentration by default.
- The goal of tumor PK modeling is not maximum complexity. The goal is a model that adequately represents the processes needed to answer the scientific question.
Where to Go Next
A natural progression from tumor drug distribution is to study target-mediated drug disposition (TMDD), followed by nonlinear pharmacokinetics from target binding, mechanistic PK/PD models, physiologically based pharmacokinetic models, and systems pharmacology of monoclonal antibodies.
The next level of detail is to replace the single tumor compartment with vascular, interstitial, and cellular compartments and derive how permeability, diffusion, target binding, internalization, and intracellular turnover jointly determine tumor exposure.
Selected References
- Jain RK. Transport of molecules, particles, and cells in solid tumors. Annual Review of Biomedical Engineering.
- Jain RK. Delivery of molecular and cellular medicine to solid tumors. Advanced Drug Delivery Reviews.
- Thurber GM, Wittrup KD. Quantitative spatiotemporal analysis of antibody penetration in tumor spheroids and tissues.
- Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nature Reviews Cancer.
- Danhier F. To exploit the tumor microenvironment: tumor-targeting nanomedicines.
- Wilkinson EM, et al. Pharmacokinetic and pharmacodynamic considerations in tumor drug distribution and exposure.
These references provide starting points for the physiological, pharmacokinetic, and pharmacometric concepts discussed in this tutorial. Specific quantitative models should be selected and validated according to the drug, tumor type, experimental system, and available data.